CytomX Therapeutics, Inc. SEC filings CTMX
CytomX Therapeutics, Inc. has 800 filings in SEC EDGAR's recent list, going back to Sep 28, 2010. Its latest annual report, Form 10-K, was filed on Mar 16, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Aug 18, 2025 | — |
| CORRESP | Letter to the SEC | Aug 14, 2025 | — |
| UPLOAD | Letter from the SEC | Aug 13, 2025 | — |
| EFFECT | Filing | Aug 19, 2024 | — |
| CORRESP | Letter to the SEC | Aug 15, 2024 | — |
| UPLOAD | Letter from the SEC | Aug 15, 2024 | — |
| EFFECT | Filing | Aug 25, 2023 | — |
| CORRESP | Letter to the SEC | Aug 23, 2023 | — |
| UPLOAD | Letter from the SEC | Aug 22, 2023 | — |
| D | Filing | Aug 17, 2023 | — |
| CT ORDER | Filing | Sep 26, 2022 | — |
| CT ORDER | Filing | Dec 29, 2021 | — |
| EFFECT | Filing | Aug 18, 2021 | — |
| CORRESP | Letter to the SEC | Aug 16, 2021 | — |
| UPLOAD | Letter from the SEC | Aug 12, 2021 | — |
| SEC STAFF LETTER | Filing | Mar 5, 2021 | — |
| SEC STAFF LETTER | Filing | Feb 4, 2021 | — |
| UPLOAD | Letter from the SEC | Apr 29, 2020 | — |
| CORRESP | Letter to the SEC | Apr 28, 2020 | — |
| EFFECT | Filing | Feb 11, 2019 | — |
| CORRESP | Letter to the SEC | Feb 8, 2019 | — |
| CT ORDER | Filing | Nov 19, 2018 | — |
| CT ORDER | Filing | Nov 19, 2018 | — |
| CT ORDER | Filing | Nov 15, 2017 | — |
| CT ORDER | Filing | Jun 13, 2017 | — |
| EFFECT | Filing | Mar 20, 2017 | — |
| CORRESP | Letter to the SEC | Mar 17, 2017 | — |
| EFFECT | Filing | Dec 7, 2016 | — |
| CORRESP | Letter to the SEC | Dec 5, 2016 | — |
| UPLOAD | Letter from the SEC | Nov 21, 2016 | — |
| CT ORDER | Filing | Oct 5, 2016 | — |
| CT ORDER | Filing | Oct 8, 2015 | — |
| EFFECT | Filing | Oct 7, 2015 | — |
| CERTNAS | Auto-generated paper document | Oct 7, 2015 | — |
| 8-A12B | Filing | Oct 6, 2015 | — |
| CORRESP | Letter to the SEC | Oct 5, 2015 | — |
| CORRESP | Letter to the SEC | Sep 22, 2015 | — |
| UPLOAD | Letter from the SEC | Sep 21, 2015 | — |
| CORRESP | Letter to the SEC | Sep 18, 2015 | — |
| CORRESP | Letter to the SEC | Sep 18, 2015 | — |
| UPLOAD | Letter from the SEC | Sep 17, 2015 | — |
| UPLOAD | Letter from the SEC | Sep 8, 2015 | — |
| UPLOAD | Letter from the SEC | Aug 19, 2015 | — |
| DRS | Filing | Jul 24, 2015 | — |
| D | Filing | Jun 25, 2015 | — |
| D | Filing | Jan 6, 2015 | — |
| D | Filing | Aug 10, 2012 | — |
| D | Filing | Sep 28, 2010 | — |
| D | Filing | Sep 28, 2010 | — |
| D | Filing | Sep 28, 2010 | — |
| D | Filing | Sep 28, 2010 | — |
| D | Filing | Sep 28, 2010 | — |
Showing 52 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CTMX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- South San Francisco, CA
- SEC filer status
- Accelerated filer
- SEC CIK
- 1501989
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.